(Q37355059)

19 August 2017

5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study (English)

1 reference

19 August 2017

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study (English)

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6600885

24 December 2023

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6600885

24 December 2023

1 reference

5

P. Loadman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698178

24 December 2023

author name string

Phase I/II Trials Committee of Cancer Research UK

11

1 reference

19 August 2017

G. J S. Rustin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698178

24 December 2023

C. Bradley

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698178

24 December 2023

S. Galbraith

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698178

24 December 2023

M. Stratford

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698178

24 December 2023

S. Waller

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698178

24 December 2023

K. Bellenger

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698178

24 December 2023

L. Gumbrell

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698178

24 December 2023

L. Folkes

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698178

24 December 2023

G. Halbert

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698178

24 December 2023

language of work or name

English

0 references

publication date

1 April 2003

1 reference

19 August 2017

22 April 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12698178

full work available at URL

24 December 2023

https://www.nature.com/articles/6600885.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698178

https://europepmc.org/articles/PMC2747563

24 December 2023

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698178

https://europepmc.org/articles/PMC2747563?pdf=render

24 December 2023

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698178

http://www.nature.com/articles/6600885.pdf

24 December 2023

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6600885

http://www.nature.com/articles/6600885

24 December 2023

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6600885

British Journal of Cancer

24 December 2023

published in

1 reference

19 August 2017

88

1 reference

19 August 2017

8

1 reference

19 August 2017

1160-1167

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6600885

19 August 2017

0 references

cites work

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747563

Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747563

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747563

Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747563

Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747563

Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747563

Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747563

Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747563

Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512).

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747563

Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747563

Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747563

Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747563

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747563

Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747563

Vinca alkaloids: anti-vascular effects in a murine tumour

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747563

Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid

2 September 2018

1 reference

12 December 2020

Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug

1 reference

12 December 2020

Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid

1 reference

12 December 2020

Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects

1 reference

12 December 2020

Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid

1 reference

12 December 2020

Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate

1 reference

12 December 2020

Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent

1 reference

12 December 2020

Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice

1 reference

12 December 2020

Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours

1 reference

12 December 2020

Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action

1 reference

12 December 2020

Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma

1 reference

12 December 2020

Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown

1 reference

12 December 2020

Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids

1 reference

12 December 2020

Studies with a Panel of Tumours Having a Variable Sensitivity to FAA, to Investigate Its Mechanism of Action

1 reference

12 December 2020

A comparison of vascular-mediated tumor cell death by the necrotizing agents gr63178 and flavone acetic acid

1 reference

12 December 2020

Short report: Phase II trial with Flavone Acetic Acid (NSC.347512, LM975) in patients with non-small cell lung cancer

1 reference

12 December 2020

Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid

1 reference

12 December 2020

Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid

1 reference

12 December 2020

The morphological effects of the anti-tumor agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumor

1 reference

12 December 2020

Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents

1 reference

12 December 2020

Measurement of nitrite and nitrate by high-performance ion chromatography

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600885

7 January 2021

inferred from DOI database lookup

British Journal of Cancer

12

80

247

MR Horsman

1999

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6600885

24 December 2023

Cancer Treatment Reports

24

70

631

J Plowman

1986

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6600885

Drug Metabolism and Disposition

24 December 2023

32

23

363

LK Webster

1995

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6600885

24 December 2023

Identifiers

1 reference

Dimensions Publication ID

19 August 2017

0 references

1 reference

19 August 2017

1 reference